CELLINK behind the scenes

Follow our financial story in the future of medicine.

On this page you can find financial reports, news, and other information regarding CELLINK. Subscribe to our page in order to get all the latest updates.

Press releases

13 April 2018 CELLINK releases 7 new Bioinks, 3 new Kits, and standardized GelMA, to Enable the Bioprinting of Multifaceted Vascularized Constructs such as Skin CELLINK releases 7 new Bioinks, 3 new Kits, and standardized GelMA, to Enable the Bioprinting of Multifaceted Vascularized Constructs such as Skin
13 April 2018 CELLINK lanserar 7 nya Biobläck, 3 nya kits med GelMA samt möjliggör 3D-Bioprinting av mångfasetterade vaskulära nätverk CELLINK lanserar 7 nya Biobläck, 3 nya kits med GelMA samt möjliggör 3D-Bioprinting av mångfasetterade vaskulära nätverk
19 March 2018 CELLINK publishes article about bioink together with world renowned scientists CELLINK publishes article about bioink together with world renowned scientists
8 February 2018 CELLINK launches the CELLINK X Bioink Series CELLINK launches the CELLINK X Bioink Series
1 February 2018 CELLINK opens office at Kyoto University in Japan CELLINK opens office at Kyoto University in Japan
17 January 2018 CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub
17 January 2018
Regulatory
Quarterly report 1 for the period 1st of September – 30th of November Quarterly report 1 for the period 1st of September – 30th of November
8 January 2018 CELLINK signs collaboration agreement with CTIBIOTECH for Bioprinting of patient-specific cancer tumors CELLINK signs collaboration agreement with CTIBIOTECH for Bioprinting of patient-specific cancer tumors
20 December 2017
Regulatory
Communication from the Annual General Meeting on 14 December Communication from the Annual General Meeting on 14 December
27 November 2017 CELLINK has been granted project funding from Horizon 2020 CELLINK has been granted project funding from Horizon 2020
15 November 2017 CELLINK enters a collaborative research program with Takara Bio CELLINK enters a collaborative research program with Takara Bio
19 October 2017
Regulatory
End of the year report for the period 1 of September – 31st of August and Quarterly report 4 End of the year report for the period 1 of September – 31st of August and Quarterly report 4
6 October 2017
Regulatory
CELLINK closes a directed share issue of SEK 30 million to Handelsbanken Fonder CELLINK closes a directed share issue of SEK 30 million to Handelsbanken Fonder
27 September 2017 CELLINK signs collaboration agreement with MIT CELLINK signs collaboration agreement with MIT
25 September 2017 CELLINK receives design patent CELLINK receives design patent
14 August 2017 Several new publications with CELLINKs technology Several new publications with CELLINKs technology
19 July 2017
Regulatory
CELLINK publishes quarterly report for the third quarter CELLINK publishes quarterly report for the third quarter
12 July 2017
Regulatory
CELLINK completes a directed share issue of 30 million SEK CELLINK completes a directed share issue of 30 million SEK
10 July 2017
Regulatory
CELLINK signs distribution agreement with Thermo Fisher Scientific ANZ CELLINK signs distribution agreement with Thermo Fisher Scientific ANZ
9 June 2017
Regulatory
CELLINK receives orders for products in conjunction with expansion CELLINK receives orders for products in conjunction with expansion
23 May 2017 CELLINK speaks of breakthrough in Bioprinting at an international conference CELLINK speaks of breakthrough in Bioprinting at an international conference
17 March 2017
Regulatory
CELLINK AB has appointed an Advisory Board CELLINK AB has appointed an Advisory Board
12 January 2017
Regulatory
CELLINK launches BIO X, a new 3D-Bioprinter CELLINK launches BIO X, a new 3D-Bioprinter
7 December 2016 CELLINK launches BioVerse - a platform for 3D-Bioprinting CELLINK launches BioVerse - a platform for 3D-Bioprinting
Show more

Ownership information

Owner A-stock B-stock Ownership Voting Right
Gatenholm, Erik 207 031 2 580 309 36.84% 42.5%
Martinez Avila, Hector Daniel 136 719 1 713 121 24.45% 28.15%
Fore C Investment Holding AB 724 808 9.58% 6.62%
Handelsbanken Fonder 383 087 5.06% 3.5%
Danielsson, Gusten 15 625 215 785 3.06% 3.4%
Svanberg, Jockum 15 625 192 708 2.75% 3.19%
Carl Bennet AB 283 599 3.75% 2.59%
Dinkelspiel, Claes 160 785 2.12% 1.47%
Nordlund, Jonas 103 154 1.36% 0.94%
Västkustens Affärsänglar AB 68 728 0.91% 0.63%
Other owners 765 679 10.12% 7.00%
Totalt 375 000 7 191 763 100.0% 100.0%

Management

Erik Gatenholm
CEO
Hector Martinez
CTO
Gusten Danielsson
CFO

Board of directors

Göran Nordlund
Chairman of the board
Göran Norlund is a contractor, private investor and board member. Since 2002, he has worked with a well-developed network of entrepreneurs to effectively invest in and build value in entrepreneurial companies. Several of these companies have been able to show very high profitable growth during these years and have also provided a good return on the way to all its shareholders.
Erik Gatenholm
Board Member
Erik Gatenholm is a serial entrepreneur and CEO/Co-Founder of CELLINK. The entrepreneurial and biotech world fascinated Gatenholm from an early age. Gatenholm started his first biomedical device company known as BC Genesis at age 18 in Blacksburg, Virginia in 2008 to commercialize a licensed university technology. BC Genesis focused on developing cellulose based medical implants for applications such as meniscus/cartilage repair as well as surgical meshes. Throughout his undergraduate studies in Management at Virginia Tech University, Gatenholm continued his work with BC Genesis and began brainstorming for his future. In 2014 he moved to Sweden to complete his MBA at Gothenburg University, focusing on the commercialization of biotechnology startups. After meeting Dr. Hector Martinez at Chalmers University in late 2014, they begun to work to commercialize the biomaterial innovation behind CELLINK.
Hector Martinez
Board Member
Hector Martinez is the CTO/Co-Founder of CELLINK. Martinez has contributed his knowledge of tissue engineering and the 3D Bioprinting field to drive CELLINK to where it is today. Martinez received his doctorate in Cartilage Tissue Engineering from Chalmers University of Technology and has 7 years of experience in biomaterials, tissue engineering and 3D bioprinting technologies. He obtained a B.Sc. in Mechanical Engineering from the University of Texas at Arlington and M.Sc. in Biomedical Engineering from Chalmers University of Technology in Sweden.
Bengt Sjöholm
Board Member
Bengt Sjöholm is a former football player and Swedish champion in Halmstad's BK and also former chairman of the same club. Sjöholm has been CEO of several Swedish companies, including Tylö AB, where he was CEO between 2004 and 2009. During the 1990s, Sjöholm was acting as CEO of a subsidiary of Getinge AB.
Klementina Österberg
Board Member
Klementina Östberg is CEO of GU Ventures. She is an expert in finance, business and company development with experience of company board work, investments, protection and commercialisation of IPR and marketing. Direct experience with management, business development and venture capital. Interested in early-stage startups as well as creating partnerships with the academia, healthcare and industry.
Artur Aira
Board Member
Arthur Aira is a medical tech engineer and MBA by training. Aira received his engineering and med tech degree at Chalmers University. Prior to his role as Executive Vice President at AddLife, Aira worked various leadership roles for the past 20 years at Organon Teknika, bioMerieux and AddTech Life Science where he served as both the Vice President and President/CEO.
Ingela Hallberg
Board Member
Ingela Hallberg is doctor by training. She received her medical degree at Gothenburg University. Hallberg started her career as a physician at Sahlgrenska University Hospital in Gothenburg. After several years at Sahlgrenska, Hallberg then spent the next 20 years working in leadership roles for various pharma industry leaders such as Bayer Healthcare, Lundbeck, Quintiles and Merck.
Andreas Albertsson
Deputy Board Member
Andreas Albertsson is a business developer who likes to create business opportunities based on innovations or know-how. Have for the last 10 years worked hands on with commercialization of innovations, entrepreneurship, management, venture creation, venture capital and regional development.

Certified Advisor

Mangold Fondkommission AB tel. 08-50301550

First North

Nasdaq First North is an alternative market, operated by the different exchanges within Nasdaq OMX. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market. All companies whose shares are traded on First North have a certified adviser who monitors the company’s compliance with First North’s rules regarding the disclosure of information to the market and investors.

Videos

Finwire TV visits CELLINK
The future of Medicine

Calendar

17-January-2018         Interim Repor September – November 2017
11-April-2018         Interim Repor December – February 2018
11-July-2018         Interim Repor March– May 2018
24-October-2018         Interim Repor June – August 2017 and end of year report
14-November-2018         Annual report
13-December-2018         Annual general meeting

CELLINK bakom kulisserna

Följ vår resa mot framtidens medicin.

På denna sida så finner ni finansiella rapporter, nyheter, och annan information om CELLINK. Prenumerera på vår sida för att ta del av de senaste uppdateringarna om CELLINK.

Pressmeddelanden

19 April 2018 CELLINK ingår partnerskap med ARMI BioFab USA, UNH Manchester för regenerativtillverkningsevenemang CELLINK ingår partnerskap med ARMI BioFab USA, UNH Manchester för regenerativtillverkningsevenemang
11 April 2018
Regulatory
CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat
9 April 2018 CELLINK WINS RED DOT AWARD FOR BIO X CELLINK WINS RED DOT AWARD FOR BIO X
9 April 2018 CELLINK VINNER RED DOT AWARD FÖR BIO X CELLINK VINNER RED DOT AWARD FÖR BIO X
19 March 2018 CELLINK publicerar artikel om biobläck tillsammans med världsledande forskare CELLINK publicerar artikel om biobläck tillsammans med världsledande forskare
8 February 2018 CELLINK lanserar CELLINK X Bioinks CELLINK lanserar CELLINK X Bioinks
1 February 2018 CELLINK öppnar kontor på Kyoto University i Japan CELLINK öppnar kontor på Kyoto University i Japan
17 January 2018 CELLINK etablerar ett forsknings- och utvecklingslaboratorie i AstraZenecas BioVentureHub CELLINK etablerar ett forsknings- och utvecklingslaboratorie i AstraZenecas BioVentureHub
17 January 2018
Regulatory
Kvartalsrapport 1 (Q1) för 1 september 2017 – 30 november 2017 Kvartalsrapport 1 (Q1) för 1 september 2017 – 30 november 2017
8 January 2018 CELLINK ingår ett samarbetsavtal med CTIBIOTECH för att skriva ut patientspecifika cancertumörer CELLINK ingår ett samarbetsavtal med CTIBIOTECH för att skriva ut patientspecifika cancertumörer
20 December 2017
Regulatory
Kommuniké från årsstämma den 14 december Kommuniké från årsstämma den 14 december
27 November 2017 CELLINK har blivit beviljat projektfinansiering från Horizon 2020 CELLINK har blivit beviljat projektfinansiering från Horizon 2020
16 November 2017
Regulatory
Publicering av CELLINKs årsredovisning för 2016/2017 Publicering av CELLINKs årsredovisning för 2016/2017
15 November 2017 CELLINK ingår ett utvecklingssamarbete med Takara Bio CELLINK ingår ett utvecklingssamarbete med Takara Bio
15 November 2017
Regulatory
Kallelse till årsstämma i CELLINK AB Kallelse till årsstämma i CELLINK AB
19 October 2017
Regulatory
Bokslutskommuniké för 1 september 2016 – 31 augusti 2017 samt kvartalsrapport 4 Bokslutskommuniké för 1 september 2016 – 31 augusti 2017 samt kvartalsrapport 4
6 October 2017
Regulatory
CELLINK genomför riktad nyemission av B-aktier om 30 MSEK till Handelsbanken Fonder CELLINK genomför riktad nyemission av B-aktier om 30 MSEK till Handelsbanken Fonder
27 September 2017 CELLINK tecknar samarbetsavtal med MIT CELLINK tecknar samarbetsavtal med MIT
25 September 2017 CELLINK beviljas mönsterskydd CELLINK beviljas mönsterskydd
14 August 2017 Nya publikationer med CELLINKs teknologier Nya publikationer med CELLINKs teknologier
19 July 2017
Regulatory
CELLINK offentliggör kvartalsrapport för tredje kvartalet CELLINK offentliggör kvartalsrapport för tredje kvartalet
12 July 2017
Regulatory
CELLINK genomför riktad nyemission av B-aktier om 30 MSEK CELLINK genomför riktad nyemission av B-aktier om 30 MSEK
10 July 2017
Regulatory
CELLINK tecknar distributionsavtal med Thermo Fisher Scientific ANZ CELLINK tecknar distributionsavtal med Thermo Fisher Scientific ANZ
9 June 2017
Regulatory
CELLINK tar emot ordrar av produkter i samband med expansion CELLINK tar emot ordrar av produkter i samband med expansion
23 May 2017 CELLINK talar om genombrott inom Bioprintning på internationell konferens CELLINK talar om genombrott inom Bioprintning på internationell konferens
12 April 2017
Regulatory
CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat
17 March 2017
Regulatory
CELLINK AB har tillsatt en Advisory Board CELLINK AB har tillsatt en Advisory Board
18 January 2017
Regulatory
CELLINK offentliggör sin första kvartalsrapport CELLINK offentliggör sin första kvartalsrapport
12 January 2017
Regulatory
CELLINK lanserar BIO X, en ny 3D-Bioprinter CELLINK lanserar BIO X, en ny 3D-Bioprinter
7 December 2016 CELLINK lanserar BioVerse - en Internet-plattform för 3D-Bioprinting CELLINK lanserar BioVerse - en Internet-plattform för 3D-Bioprinting
15 November 2016
Regulatory
CELLINK: Styrelseledamot avgår CELLINK: Styrelseledamot avgår
15 November 2016 CELLINK: Förtydligande av information med anledning av informationsläckage CELLINK: Förtydligande av information med anledning av informationsläckage
26 October 2016 CELLINKs erbjudande tecknades till 1 070 procent – Handel på Nasdaq First North inleds den 3 november 2016 CELLINKs erbjudande tecknades till 1 070 procent – Handel på Nasdaq First North inleds den 3 november 2016
12 October 2016 CELLINK AB har blivit beviljat projektfinansiering från Horizon 2020 CELLINK AB har blivit beviljat projektfinansiering från Horizon 2020
6 October 2016 CELLINK offentliggör investeringsmemorandum med anledning av nyemission riktad till allmänheten i samband med planerade listning på Nasdaq First North CELLINK offentliggör investeringsmemorandum med anledning av nyemission riktad till allmänheten i samband med planerade listning på Nasdaq First North
Show more

Video

Finwire TV besöker CELLINK
Framtiden för medicin

Uppgifter om aktieägare

 

Ägare A-aktier B-aktier Ägarandel Röstvärde
Gatenholm, Erik 207 031 2 580 309 36.84% 42.5%
Martinez Avila, Hector Daniel 136 719 1 713 121 24.45% 28.15%
Fore C Investment Holding AB 724 808 9.58% 6.62%
Handelsbanken Fonder 383 087 5.06% 3.5%
Danielsson, Gusten 15 625 215 785 3.06% 3.4%
Svanberg, Jockum 15 625 192 708 2.75% 3.19%
Carl Bennet AB 283 599 3.75% 2.59%
Claes Dinkelspiel 160 785 2.12% 1.47%
Jonas Nordlund 103 154 1.36% 0.94%
Västkustens Affärsänglar AB 68 728 0.91% 0.63%
Other owners 765 679 10.12% 7.00%
Totalt 375 000 7 191 763 100.0% 100.0%

 

Ledningsgrupp

Erik Gatenholm
CEO
Hector Martinez
CTO
Gusten Danielsson
CFO

Styrelse

Göran Nordlund
Styrelseordförande
Erik Gatenholm
Styrelseledamot
Hector Martinez
Styrelseledamot
Bengt Sjöholm
Styrelseledamot
Klementina Österberg
Styrelseledamot
Andreas Albertsson
Suppleant

Certified Advisor

Mangold Fondkommission AB tel. 08-50301550

First North

First North är en alternativ marknadsplats som drivs av de olika börserna som ingår i Nasdaq OMX. Den har inte samma juridiska status som en reglerad marknad. Bolag på First North regleras av First North regler och inte av de juridiska krav som ställs för handel på en reglerad marknad. En placering i ett bolag som handlas på First North är mer riskfylld än en placering i ett börsnoterat bolag. Alla företag vars aktier handlas på First North har en certifierad rådgivare som övervakar bolagets överensstämmelse med First Norths regler om information till marknaden och investerare.

Kalendarium

17-januari-2018         Delårsrapport september – november 2017
11-april-2018         Delårsrapport december – februari 2018
11-juli-2018         Delårsrapport mars – maj 2018
24-oktober-2018         Delårsrapport juni – augusti 2017 samt bokslutskommuniké
14-november-2018         Årsredovisning
13-december-2018         Årsstämma